Literature DB >> 19184068

Mechanisms of tau-induced neurodegeneration.

Khalid Iqbal1, Fei Liu, Cheng-Xin Gong, Alejandra Del C Alonso, Inge Grundke-Iqbal.   

Abstract

Alzheimer disease (AD) and related tauopathies are histopathologically characterized by a specific type of slow and progressive neurodegeneration, which involves the abnormal hyperphosphorylation of the microtubule associated protein (MAP) tau. This hallmark, called neurofibrillary degeneration, is seen as neurofibrillary tangles, neuropil threads, and dystrophic neurites and is apparently required for the clinical expression of AD, and in related tauopathies it leads to dementia in the absence of amyloid plaques. While normal tau promotes assembly and stabilizes microtubules, the non-fibrillized, abnormally hyperphosphorylated tau sequesters normal tau, MAP1 and MAP2, and disrupts microtubules. The abnormal hyperphosphorylation of tau, which can be generated by catalysis of several different combinations of protein kinases, also promotes its misfolding, decrease in turnover, and self-assembly into tangles of paired helical and or straight filaments. Some of the abnormally hyperphosphorylated tau ends up both amino and C-terminally truncated. Disruption of microtubules by the non-fibrillized abnormally hyperphosphorylated tau as well as its aggregation as neurofibrillary tangles probably impair axoplasmic flow and lead to slow progressive retrograde degeneration and loss of connectivity of the affected neurons. Among the phosphatases, which regulate the phosphorylation of tau, protein phosphatase-2A (PP2A), the activity of which is down-regulated in AD brain, is by far the major enzyme. The two inhibitors of PP-2A, I (1) (PP2A) and I (2) (PP2A) , which are overexpressed in AD, might be responsible for the decreased phosphatase activity. AD is multifactorial and heterogeneous and involves more than one etiopathogenic mechanism.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19184068      PMCID: PMC2872491          DOI: 10.1007/s00401-009-0486-3

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  211 in total

1.  Fragmentation of the Golgi apparatus induced by the overexpression of wild-type and mutant human tau forms in neurons.

Authors:  Dalinda Liazoghli; Sebastien Perreault; Kristina D Micheva; Mylène Desjardins; Nicole Leclerc
Journal:  Am J Pathol       Date:  2005-05       Impact factor: 4.307

2.  Immunohistochemical examination of phosphorylated tau in granulovacuolar degeneration granules.

Authors:  K Ikegami; T Kimura; S Katsuragi; T Ono; H Yamamoto; E Miyamoto; T Miyakawa
Journal:  Psychiatry Clin Neurosci       Date:  1996-06       Impact factor: 5.188

Review 3.  Physiologic importance of protein phosphatase inhibitors.

Authors:  C J Oliver; S Shenolikar
Journal:  Front Biosci       Date:  1998-09-01

4.  Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments.

Authors:  M Morishima-Kawashima; M Hasegawa; K Takio; M Suzuki; K Titani; Y Ihara
Journal:  Neuron       Date:  1993-06       Impact factor: 17.173

5.  Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5.

Authors:  A Sengupta; Q Wu; I Grundke-Iqbal; K Iqbal; T J Singh
Journal:  Mol Cell Biochem       Date:  1997-02       Impact factor: 3.396

6.  The microtubule-associated protein tau forms a triple-stranded left-hand helical polymer.

Authors:  G C Ruben; K Iqbal; I Grundke-Iqbal; H M Wisniewski; T L Ciardelli; J E Johnson
Journal:  J Biol Chem       Date:  1991-11-15       Impact factor: 5.157

7.  New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry.

Authors:  D P Hanger; J C Betts; T L Loviny; W P Blackstock; B H Anderton
Journal:  J Neurochem       Date:  1998-12       Impact factor: 5.372

8.  Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease.

Authors:  M Goedert; M G Spillantini; R Jakes; D Rutherford; R A Crowther
Journal:  Neuron       Date:  1989-10       Impact factor: 17.173

9.  Phosphorylation of microtubule-associated protein tau: identification of the site for Ca2(+)-calmodulin dependent kinase and relationship with tau phosphorylation in Alzheimer tangles.

Authors:  B Steiner; E M Mandelkow; J Biernat; N Gustke; H E Meyer; B Schmidt; G Mieskes; H D Söling; D Drechsel; M W Kirschner; M Goedert; E Mandelkow
Journal:  EMBO J       Date:  1990-11       Impact factor: 11.598

10.  DJ-1 (PARK7) is associated with 3R and 4R tau neuronal and glial inclusions in neurodegenerative disorders.

Authors:  Ravindran Kumaran; Ann Kingsbury; Ian Coulter; Tammaryn Lashley; David Williams; Rohan de Silva; David Mann; Tamas Revesz; Andrew Lees; Rina Bandopadhyay
Journal:  Neurobiol Dis       Date:  2007-07-18       Impact factor: 5.996

View more
  205 in total

Review 1.  Targeting tau protein in Alzheimer's disease.

Authors:  Cheng-Xin Gong; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

2.  Overexpression of amyloid-β protein precursor induces mitochondrial oxidative stress and activates the intrinsic apoptotic cascade.

Authors:  Matthew G Bartley; Kristin Marquardt; Danielle Kirchhof; Heather M Wilkins; David Patterson; Daniel A Linseman
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

3.  The structural intolerance of the PrP alpha-fold for polar substitution of the helix-3 methionines.

Authors:  Silvia Lisa; Massimiliano Meli; Gema Cabello; Ruth Gabizon; Giorgio Colombo; María Gasset
Journal:  Cell Mol Life Sci       Date:  2010-05-09       Impact factor: 9.261

4.  Hsp70 ATPase Modulators as Therapeutics for Alzheimer's and other Neurodegenerative Diseases.

Authors:  Umesh K Jinwal; John Koren; John C O'Leary; Jeffrey R Jones; Jose F Abisambra; Chad A Dickey
Journal:  Mol Cell Pharmacol       Date:  2010-01-01

Review 5.  The Proteasome and Oxidative Stress in Alzheimer's Disease.

Authors:  Vicent Bonet-Costa; Laura Corrales-Diaz Pomatto; Kelvin J A Davies
Journal:  Antioxid Redox Signal       Date:  2016-08-25       Impact factor: 8.401

6.  Prefibrillar tau oligomers in mild cognitive impairment and Alzheimer's disease.

Authors:  Elliott J Mufson; Sarah Ward; Lester Binder
Journal:  Neurodegener Dis       Date:  2013-09-11       Impact factor: 2.977

Review 7.  Human fetal tau protein isoform: possibilities for Alzheimer's disease treatment.

Authors:  Nataša Jovanov-Milošević; Davor Petrović; Goran Sedmak; Mario Vukšić; Patrick R Hof; Goran Simić
Journal:  Int J Biochem Cell Biol       Date:  2012-05-15       Impact factor: 5.085

8.  Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I: A MOLECULAR MECHANISM LINKED TO TAU PATHOLOGY IN ALZHEIMER DISEASE.

Authors:  Nana Jin; Xiaomin Yin; Jianlan Gu; Xinhua Zhang; Jianhua Shi; Wei Qian; Yuhua Ji; Maohong Cao; Xiaosong Gu; Fei Ding; Khalid Iqbal; Cheng-Xin Gong; Fei Liu
Journal:  J Biol Chem       Date:  2015-04-27       Impact factor: 5.157

Review 9.  Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.

Authors:  Thomas Wisniewski; Allal Boutajangout
Journal:  Brain Struct Funct       Date:  2009-12-10       Impact factor: 3.270

Review 10.  Alzheimer's disease as homeostatic responses to age-related myelin breakdown.

Authors:  George Bartzokis
Journal:  Neurobiol Aging       Date:  2009-09-22       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.